Antisense Therapeutics lowers costs for MS treatment study
Posted: Tue Mar 19, 2013 2:36 am
Antisense Therapeutics lowers costs for multiple sclerosis treatment support study
Antisense Therapeutics (ASX: ANP) has significantly lowered the costs associated with its planned chronic toxicology study of the drug ATL1102.
The company now expects the study, which will support a potential future phase IIb study of ATL1102 in multiple sclerosis patients, to cost less than A300,000 to complete.
Importantly, Antisense is able to fund the study without it having a material effect on cash flow forecasts which cover planned activities well into 2014..... Read More - http://www.ms-uk.org/index.cfm/MSnews
Antisense Therapeutics (ASX: ANP) has significantly lowered the costs associated with its planned chronic toxicology study of the drug ATL1102.
The company now expects the study, which will support a potential future phase IIb study of ATL1102 in multiple sclerosis patients, to cost less than A300,000 to complete.
Importantly, Antisense is able to fund the study without it having a material effect on cash flow forecasts which cover planned activities well into 2014..... Read More - http://www.ms-uk.org/index.cfm/MSnews